The drug development space is continuing to attract more and more investment. On Thursday, another major player, Generate Biomedicines, announced a $370 million Series B round.  Generate Biomedicines is touting a platform-based approach to drug development, but with its own spin: a focus on proteins.  Generate’s thesis is simple: Rather than making connections between targets … Continue reading Generate Biomedicines raises $370M Series B with a focus on protein-based drugs